{"entity":{"id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","aka":[],"tldr":"A phase 2 trial of Regorafenib in advanced solid tumours, run by Bayer, active and no longer recruiting.","summary":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies is a phase 2 interventional study registered as NCT06246643 by Bayer, with 13 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-04-27. Interventions recorded: Regorafenib (Stivarga, BAY73-4506).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06246643","url":"https://clinicaltrials.gov/study/NCT06246643"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["regorafenib"],"companies":["bayer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06246643","phase":"2","setting":"A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study (Monotherapy or Combination Treatment) That Has Reached the Primary Completion Endpoint or the Main Data Analysis or Has Been Stopped Prematurely.","sponsor":"Bayer","enrolled":13,"outcomes":[]},"route":"/trials/nct06246643/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"}]}}